Risk factor
Limited default risk
Profitability factor
Very strong margins and returns
About
Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company distributes other products that are licensed from other laboratories. Its principal products include Hibor, a low-molecular-weight heparin to prevent and treat venous thromboembolic disease; Enoxaparin biosimilar Becat, a low-molecular-weight heparin;...
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is reasonably priced on P/E, of fair value on
Target Price
The average target price of ROVI.MC is 84 and suggests 14% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation
Buy
Sell